Sorry, you need to enable JavaScript to visit this website.
ENROLL
PATIENTS
VOWST Voyage™
Patient Support Program

DYSBIOSIS CAN MAKE RECURRENT C. DIFF* GO EXTRA ROUNDS1,2

AS EARLY AS FIRST C. DIFF RECURRENCE,
KNOCK IT OUT WITH THE

1-2

GUT PUNCH

Prescribe VOWST® following an antibiotic to deliver
superior efficacy vs an antibiotic alone3-5

SEE THE EFFICACY DATA
SEE THE SAFETY DATA
Vowst Punch Banner

AS EARLY AS FIRST C. DIFF RECURRENCE,
KNOCK IT OUT WITH THE

1-2

GUT
PUNCH

Prescribe VOWST® following an antibiotic to deliver
superior efficacy vs an antibiotic alone3-5

SEE THE EFFICACY DATA
SEE THE SAFETY DATA

*Clostridioides difficile (C. diff) infection.

VOWST is the FIRST and ONLY FDA-approved orally administered microbiome
therapeutic to prevent C. diff recurrence3,4

Boxing gloves icon

TAKE A SEQUENTIAL DUAL APPROACH TO PREVENT rCDI

with VOWST following antibiotics4,6-9

see the MOA
2-step dosing icon

2-STEP
ORAL DOSING

that is self-administered at home

GET VOWST DOSING DETAILS
clock icon

VOWST WAS USED AS EARLY AS FIRST C. DIFF RECURRENCE

in the ECOSPOR IV study10

SEE ECOSPOR IV STUDY RESULTS

ABX, antibiotics; rCDI, recurrent C. diff infection.

REFERENCES: 1. Jain N, Umar TP, Fahner A-F, Gibietis V. Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval implications. Gut Microbes. 2023;15(1):2232137. doi:10.1080/19490976.2023.2232137 2. Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(132):1-8. doi:10.1186/s12879-023-08096-0 3. VOWST [Prescribing Information]. Cambridge, MA: Seres Therapeutics, Inc. and Nestlé Health Science. 06/2024. 4. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386:220-229. doi:10.1056/NEJMoa2106516 5. Cohen SH, Louie TJ, Sims M, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA. 2022;328(20):2062-2064. doi:10.1001/jama.2022.16476 6. Vincent C, Miller MA, Edens TJ, et al. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome. 2016;4:12. doi:10.1186/s40168-016-0156-3 7. Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect. 2018;24(5):476-482. doi:10.1016/j.cmi.2017.11.017 8. McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72(12):2132-2140. doi:10.1093/cid/ciaa387 9. Khanna S, Sims M, Louie TJ, et al. SER-109: An oral investigational microbiome therapeutic for participants with recurrent Clostridioides difficile infection (rCDI). Antibiotics (Basel). 2022;11(9):1234. doi:10.3390/antibiotics11091234 10. Sims MD, Khanna S, Feuerstadt P, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Netw Open. 2023;6(2):e2255758. doi:10.1001/jamanetworkopen.2022.55758

​